This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): tetrabenazine modified-release (MR)
Description: BVF-018 is a modified-release formulation of tetrabenazine. Tetrabenazine is a dopamine-depleting drug that is closely related to the antipsychotics and has a similar mechanism of action. It specifically targets the vesicular monoamine transporter 2 (VMAT2). VMAT2 is located primarily in the brain and sympathetic neurons.
Deal Structure: BVF-018 was originally developed by Biovail.
Valeant and Biovail
In June 2010, Valeant and Biovail announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International. This acquisition closed in September 2010.
Pink Sheet Chart: Weekly Trademark Review
Additional information available to subscribers only: